Abstract
Neurological impairment is a common feature of Acquired Immunodeficiency Syndrome (AIDS); functional alterations have been reported both in central and peripheral nervous system and the Human Immunodeficiency Virus (HIV) envelope glycoprotein gp120 has been proposed as a neurotoxin acting through a calcium-dependent mechanism. On the other hand it has been reported that gp120 treatment also induce about a 20% decrease in the cerebral glucose utilization and in the cellular ATP levels. The reported observations were performed on experimental system where also non-neuronal cells where present; in order to evaluate whether a direct interaction between HIV proteins and neuronal cells takes place, we used a neuroblastoma cultures where only neuronal cells are present.
We analysed the effects of gp120 on the N18TG2 neuroblastoma clone. Treatments were performed both on growing and confluent cultures. Short time treatment with gp120 of confluent cultures causes a 25% reduction in the level of neuron-specific enolase, resulting in a similar decrease of oxygen consumption. Long time exposure of growing cells also causes a reduction in cell survival. Furthermore, using a membrane-specific fluorescent probe we observed that gp120 produces an increase of membrane trafficking. These observations suggest a direct interaction between the viral envelope protein and neuronal cells, which results in an alteration of glycolytic metabolism. This alteration may be related to the neurologic impairments observed in AIDS patients.
Similar content being viewed by others
References
De Girolami U, Smith TW, Hénin D, Hauw JJ: Neuropathology of the acquired immunodeficiency syndrome. Arch Pathol Lab Med 114: 643–665, 1990
Lipton SA: Ca2+, N-Methyl-D-Aspartate receptors, and AIDS-related neuronal injury. Int Rev Neurobiol 36: 1–27, 1994a
Glass JD, Johnson RT: Human immunodeficiency virus and the brain. Annu Rev Neurosci 19: 1–26, 1996
Giulian D, Vaca K, Noonan CA: Secretion of the neurotoxins by mononuclear phagocytes infected with HIV-1. Science 250: 1593–1596, 1990
Ho DH, Pomerantz MJ, Kaplan JC: Pathogenesis of infection with human immunodeficiency virus. New Engl J Med 315: 278–286, 1987
Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL, Ruff MR, Pert CB: Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 335: 639–642, 1988
Dreyer EB, Kaiser PK, Offermann JT, Lipton SA: HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 248: 364–367, 1990
Kaiser PK, Jeffrey BA, Offermann JT, Lipton SA: Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies. Neurology 40: 1757–1761, 1990
Lipton SA, Sucher N, Kaiser PK, Dreyer EB: Synergistic effects of HIV coat protein and NMDA receptor-mediated neurotoxicity. Neuron 7: 111–118, 1991
Sabatier JM, Vives E, Mabrouk K, Benjouabd A, Rochat H, Duval A, Hue B, Bahraoui E: Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 65: 961–967, 1991
Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L: Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367: 188–193, 1994
Nath A, Padua RA, Geiger JD: HIV-1 coat protein gp120-induced increases in levels of intrasynaptosomal calcium. Brain Res 678: 200–206, 1995
Harouse JM, Bhat S, Spitalnik SL, Laughlin M, Stefano K: Inhibition of entry of HIV-1 in neural cell lines by antibodies against galactosyl ceramide. Science 253: 320–322, 1991
Lipton SA: HIV displays its coat of arms. Nature 367: 113–114, 1994b
Lipton SA: HIV coat protein gp120 induces soluble neurotoxins in culture medium. Neurosci Res Commun 15: 31–37, 1994c.
Limoges J, Yuri P, Bock P, Gendelman HE: Dexamethasone therapy worsen the neuropathology of human immunodeficiency virus type 1 encephalitis in SCID mice. J Infect Dis 175: 1368–1371, 1997
Kimes AS, London ED, Raymon L, Tabakoff B: Reduction of cerebral glucose utilization by envelope glycoprotein gp120. Exp Neurol 112: 224–228, 1991
Deiken RF, Hubesch B, Jensen PC, Sappey-Marinier D, Krell P, Winiewski A, Vanderburg D, Parks R, Fein G, Weiner W: Alterations in brain metabolite concentrations in patient with human immunodeficiency virus infection. Arch Neurol 48: 203–209, 1991
Barks JDE, Sun R, Malinak C, Silverstein FS: gp120, an HIV-1 protein, increases susceptibility to hypoglycemic and ischemic brain injury in perinatal rats. Exp Neurol 132: 123–133, 1995
Brooke SM, Howard SA, Sapolsky RM: Energy dependency of glucocorticoid exacerbation of gp120 neurotoxicity. J Neurochem 71: 1187–1193, 1998
Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Neurochem 65: 55–63, 1983
Grasso A, Haglid KG, Hansson HA, Persson L, Rö nnback L: Localization of 14,3,2 protein in the rat brain by electronmicroscopy. Brain Res 123: 582–585, 1977
Karlsson JE, Rosengren LE, Haglid KG: A rapid HPLC method to separate the triplet proteins of neurofilament. J Neurochem 49: 1375–1378, 1987
Wang S, Rosengren LE, Karlsson JE, Stigbrand T, Haglid KH: A simple quantitative dot-immunobinding assay for glial and neuronal marker proteins in SDS-solubilized brain tissue extracts. J Neurosci Meth 33: 219–227, 1990
Brogi A, Presentini R, Solazzo D, Piomboni P, Costantino Ceccarini E: Interaction of human immunodeficiency virus type 1 envelope glycoprotein gp120 with a galactoglycerolipid associated with human sperm. AIDS Res Hum Retroviruses 12: 483–489, 1996
Kubina M, Lanza F, Cazenave J-P, Laustriat G, Kuhry J-G: Parallel investigation of exocytosis kinetics and membrane fluidity changes in human platelets with the fluorescent probe, trimethylammoniodiphenylhexatriene. Biochim Biophys Acta 901: 138–146, 1987
Illinger D, Poindron P, Fonteneau P, Modollel M, Kuhry JG: Internalization of the lipophilic fluorescent probe trimethylamino-diphenylhexatriene follows the endocytosis and recycling of the plasma membrane in cells. Biochim Biophys Acta 1030: 73–81, 1990
Heemskerk JWM, Feije MAH, Andree HAM, Sage SO: Function of intracellular [Ca2+]i in exocytosis and transbilayer movement in human platelets surface-labelled with the fluorescent probe 1-(4-(trimethylammonio) phenyl)-6-phenyl-1,3,5-hexatriene. Biochim Biophys Acta 1147: 194–204, 1993
West DC, Sattar A, Kumar S: A simplified in situ solubilization procedure for the determination of DNA and cell number in tissue cultured mammalian cells. Anal Biochem 147: 289–295, 1984
Stout DL, Becker FF: Fluorometric quantitation of single-stranded DNA: A method applicable to the technique of alkaline elution. Anal Biochem 127: 302–307, 1982
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein. Anal Biochem 72: 248–254, 1976
Chesebro B, Buller R, Portis J, Wehrly K: Failure of human immunodeficiency virus entry and infection in CD4-positive human brain and skin cells. J Virol 64: 215–221, 1990
Harouse JM, Kunsch C, Hartle HT, Laughlin M, Hoxie JA, Wigdahl B, Gonzalez-Scarano F: CD4 independent infection of human neural cells by human immunodeficiency virus type 1. J Virol 63: 2527–2533, 1989
Vesanen M, Linna T, Vaheri A: Persistent inapparent HIV-1 infection of human neuroblastoma cells. Arch Virol 120: 253–261, 1991
Bhat S, Spitalnik SL, Gonzalez-Scarano F, Silberberg DH: Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc Natl Acad Sci USA 88: 7131–7134, 1991
Dawson VL, Dawson TM, Uhl GR, Snyder SH: Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA 90: 3256–3259, 1993
Barks JDE, Liu XH, Sun R, Silverstein FS: gp120 a human immunodeficiency virus-1 coat protein, augments excitotoxic hippocampal injury in perinatal rats. Neuroscience 76: 397–409, 1997
Yusim A, Franklin L, Brooke S, Ajilore O, Sapolsky R: Glucocorticoids exacerbate the deleterious effects of gp120 in hippocampal and cortical explants. J Neurochem 74: 1000–1007, 2000
Ketzler S, Weis S, Haug H, Budka H: Loss of neurons in the frontal cortex in AIDS brains. Acta Neuropathol 80: 92–94, 1990
Everall IP, Luthert PJ, Lantos PL: Neuronal loss in the frontal cortex in HIV infection. Lancet 337: 1119–1121, 1991
Kozlowski MR, Sandler P, Lin PF, Watson A: Brain-derived cells contain a specific binding site for gp120 which is not the CD4 antigen. Brain Res 553: 300–304, 1991
Lo TM, Fallert CJ, Piser T M, Thayer SA: HIV-1 envelope protein evokes intracellular calcium oscillations in rat hippocampal neurons. Brain Res 594: 189–196, 1992
Lipton S: Neuronal injury associated with HIV-1: Approaches to treatment. Annu Rev Pharmacol Toxicol 38: 159–177, 1998
Sakimura K, Kushiya E, Ogura A, Kudo Y, Katagiri T, Takahashi Y: Upstream and intron regulatory regions for expression of the rat neuron-specific enolase gene. Mol Brain Res 2819–28, 1995
Twyman RM, Jones EA: Sequences in the proximal 5' flanking region of the rat neuron-specific enolase (NSE) gene are sufficient for cell type-specific reporter gene expression. J Mol Neurosci 8: 63–73, 1997
O'Donovan KJ, Tourtellotte WG, Milbrandt J, Baraban JM: The EGR family of transcription-regulatory factors: Progress at the interface of molecular and systems neuroscience. Trends Neurosci 22: 167–173, 1999
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vignoli, A.L., Martini, I., Haglid, K.H. et al. Neuronal glycolytic pathway impairment induced by HIV envenlope glyocprotein gp120. Mol Cell Biochem 215, 73–80 (2000). https://doi.org/10.1023/A:1026590916661
Issue Date:
DOI: https://doi.org/10.1023/A:1026590916661